Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV versus high-dose subcutaneous secukinumab in partial responders with chronic plaque psoriasis
2011-002510-36Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoints: PASI 75 response and IGA 0 or 1 response. Started Sep 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2011-002510-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002510-36.